Navigation Links
Isis Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
Date:9/4/2013

CARLSBAD, Calif., Sept. 4, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 2:05 p.m. ET in New York, NY.

(Logo:  http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 29 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.  In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
2. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
6. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
7. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
8. AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
9. Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
10. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
11. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage ... today announced further details of three new clinical ... of Lewy body dementia, a disease affecting approximately ... of the three studies were recently initiated and ... quarter. In addition, the Company reported financial results ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment ... reveals that global diagnostic ultrasound devices market was valued at US$ ... million by 2019 at a CAGR of 6.8% from 2015 to ... has been analyzed for six geographies of North America ... , Latin America , Middle-East ...
(Date:2/9/2016)... 2016 The new report "Global Blood Monitoring & Cardiac Monitoring Devices ... Consulting group reveals that global market for blood monitoring & cardiac ... expected to grow to US$ 24,830.1 million by 2019 at a ... America , Europe , Asia-Pacific ... and Africa . The three major ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise ... enterprises move workloads to the cloud. Cirracore provides a secure VMware® vCloud ... traversing the Internet. Transformation Solutions (TSL Partners) provides a full range of ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ program into ... prescription referral received at our specialty pharmacy. , “Since our Pay It ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul ... appointment after they noticed their furnace not producing any heat. Shortly after entering the ... cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, at ...
(Date:2/9/2016)... ... February 09, 2016 , ... The ... Herberger’s and Younkers department stores, announced it has raised $176,000 to benefit the ... Holden Comprehensive Cancer Center at the University of Iowa, The Lynn Sage Cancer ...
(Date:2/9/2016)... ... 09, 2016 , ... ZipHearing.com is proud to ... hearing aids , increase industry transparency, and promote awareness of hearing solutions ... “For the average consumer, the hearing aid industry is esoteric and difficult to ...
Breaking Medicine News(10 mins):